Gilead Sciences, Inc. has announced that it has received new approval from the U.S. Food and Drug Administration (FDA) for a ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Gilead's lenacapavir reduced HIV infections by 96% in Phase 3 trials, surpassing Truvada. Gilead plans to begin Phase 3 study for once-yearly lenacapavir in 2025, with regulatory filings in 2027.

After purging the CDC’s vaccine advisory committee and replacing it with his own appointments, U.S. Health Secretary Robert F ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, ...

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate settlement with Gilead Sciences, Inc. over an illegal kickback scheme to ...

Biopharmaceuticals stock Gilead Sciences ( GILD 3.08%) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...